COMPASS Pathways plc (CMPS)

NASDAQ: CMPS · IEX Real-Time Price · USD
10.70
-0.02 (-0.19%)
At close: Jan 27, 2023, 4:00 PM
10.45
-0.25 (-2.34%)
After-hours: Jan 27, 2023, 6:55 PM EST
-0.19%
Market Cap 455.57M
Revenue (ttm) n/a
Net Income (ttm) -86.23M
Shares Out 42.58M
EPS (ttm) -2.05
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 287,639
Open 10.83
Previous Close 10.72
Day's Range 10.64 - 10.92
52-Week Range 6.54 - 21.50
Beta 2.29
Analysts Buy
Price Target 46.83 (+337.66%)
Earnings Date Feb 23, 2023

About CMPS

COMPASS Pathways plc operates as a mental health care company primarily in the United Kingdom and the United States. It develops COMP360, a psilocybin therapy that has completed Phase IIb clinical trials for the treatment of treatment-resistant depression; and is in Phase II clinical trials for the treatment of post-traumatic stress disorder. The company was formerly known as COMPASS Rx Limited and changed its name to COMPASS Pathways plc in August 2020. COMPASS Pathways plc was incorporated in 2020 and is headquartered in London, the United Ki... [Read more]

Sector Healthcare
IPO Date Sep 18, 2020
Employees 116
Stock Exchange NASDAQ
Ticker Symbol CMPS
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecast

According to 18 analysts, the average rating for CMPS stock is "Buy." The 12-month stock price forecast is $46.83, which is an increase of 337.66% from the latest price.

Price Target
$46.83
(337.66% upside)
Analyst Consensus: Buy
Stock Forecasts

News

All You Need to Know About COMPASS Pathways PLC Sponsored ADR (CMPS) Rating Upgrade to Strong Buy

COMPASS Pathways PLC Sponsored ADR (CMPS) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).

2 weeks ago - Zacks Investment Research

Are Medical Stocks Lagging COMPASS Pathways (CMPS) This Year?

Here is how COMPASS Pathways PLC Sponsored ADR (CMPS) and Geron (GERN) have performed compared to their sector so far this year.

2 weeks ago - Zacks Investment Research

7 Stocks Under $20 to Buy and Hold Forever

It is currently as good a time as ever for long-term investors to buy stocks. With that in mind, I decided to look for seven cheap stocks trading under $20  to buy and hold forever.

Other symbols: AMZNFFSRMPWPRTSTOST
1 month ago - InvestorPlace

COMP360 psilocybin therapy shows potential in open-label study in type II bipolar disorder presented at ACNP

12 out of 14 patients went into remission for three months following a single 25mg dose of COMP360 psilocybin therapy, in an independent investigator-initiated, exploratory open-label study of type II...

1 month ago - GlobeNewsWire

COMPASS Pathways to participate in upcoming Evercore ISI HealthCONx Conference

LONDON, Nov. 28, 2022 (GLOBE NEWSWIRE) -- COMPASS Pathways plc (Nasdaq: CMPS), a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health, anno...

2 months ago - GlobeNewsWire

COMPASS Pathways Announces Third Quarter 2022 Financial Results and Business Highlights

LONDON, Nov. 03, 2022 (GLOBE NEWSWIRE) -- COMPASS Pathways plc (Nasdaq: CMPS) (“COMPASS”), a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental ...

3 months ago - GlobeNewsWire

COMPASS Pathways announces publication of phase 2b study of COMP360 psilocybin therapy for treatment-resistant depression in The New England Journal of Medicine

After a single 25mg dose of COMP360 psilocybin therapy, approximately 30% of patients with

3 months ago - GlobeNewsWire

COMPASS Pathways plc to announce third quarter 2022 financial results on 3 November 2022

LONDON, Oct. 26, 2022 (GLOBE NEWSWIRE) -- COMPASS Pathways plc (Nasdaq: CMPS), a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health, anno...

3 months ago - GlobeNewsWire

COMPASS Pathways PLC Sponsored ADR (CMPS) Upgraded to Buy: What Does It Mean for the Stock?

COMPASS Pathways PLC Sponsored ADR (CMPS) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near ...

3 months ago - Zacks Investment Research

COMPASS Pathways Announces Phase 3 Pivotal Program Design for COMP360 in Treatment Resistant Depression at Capital Markets Day

First ever phase 3 program of psilocybin therapy globally scheduled to begin in 2022 First ever phase 3 program of psilocybin therapy globally scheduled to begin in 2022

3 months ago - GlobeNewsWire

COMPASS Pathways to Hold Virtual Capital Market Day on 12 October 2022

LONDON, Oct. 04, 2022 (GLOBE NEWSWIRE) -- COMPASS Pathways plc (Nasdaq: CMPS), a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health, anno...

4 months ago - GlobeNewsWire

COMPASS Pathways to participate in upcoming Jefferies Innovation in Mental Health Summit

LONDON, Sept. 19, 2022 (GLOBE NEWSWIRE) -- COMPASS Pathways plc (Nasdaq: CMPS), a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health, ann...

4 months ago - GlobeNewsWire

Compass Pathways (CMPS): The McDonald's of Psychedelics?

This week, we're talking about my Big Three investing themes for the rest of the year (and beyond). You've probably heard me talk about each at one point or another.

5 months ago - InvestorPlace

COMPASS Pathways to participate in three upcoming investor events

LONDON, Sept. 01, 2022 (GLOBE NEWSWIRE) -- COMPASS Pathways plc (Nasdaq: CMPS), a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health, ann...

5 months ago - GlobeNewsWire

7 Psychedelics Stocks to Buy for a Big Drug Boom

Psychedelics stocks are becoming increasingly mainstream, in part due to changing social attitudes. Psychedelic drugs “are a loosely grouped class of drugs that are able to induce altered thoughts and...

5 months ago - InvestorPlace

One Mind Announces the Winners of the 2022 Rising Star Awards for Mental Health Research

RUTHERFORD, Calif.--(BUSINESS WIRE)--One Mind, in collaboration with COMPASS Pathways plc, has announced the recipients of three “2022 One Mind – COMPASS Rising Stars Awards."

5 months ago - Business Wire

3 Best Psychedelic Stocks to Buy Now

The incredible healing properties of psychedelics are being discovered with every passing day. Their potential is massive and can flip the script for those struggling with mental health disorders.

Other symbols: CYBNMNMD
6 months ago - InvestorPlace

Wall Street Analysts See a 289% Upside in COMPASS Pathways PLC Sponsored ADR (CMPS): Can the Stock Really Move This High?

The consensus price target hints at a 288.6% upside potential for COMPASS Pathways PLC Sponsored ADR (CMPS). While empirical research shows that this sought-after metric is hardly effective, an upward...

6 months ago - Zacks Investment Research

COMPASS Pathways plc announces second quarter 2022 financial results and business highlights

LONDON, Aug. 04, 2022 (GLOBE NEWSWIRE) -- COMPASS Pathways plc (Nasdaq: CMPS) (“COMPASS”), a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental ...

6 months ago - GlobeNewsWire

COMPASS Pathways launches phase II clinical trial of psilocybin therapy in anorexia nervosa

Multi-centre, d ouble-blind randomised controlled phase II trial will investigate the efficacy of COMP360 psilocybin therap y in anorexia nervosa for which there is currently no approved pharmacologic...

6 months ago - GlobeNewsWire

COMPASS Pathways plc to announce second quarter 2022 financial results on 4 August 2022

LONDON, July 26, 2022 (GLOBE NEWSWIRE) -- COMPASS Pathways plc (Nasdaq: CMPS), a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health, anno...

6 months ago - GlobeNewsWire

Dear Psychedelic Stocks Fans, Watch This Key Catalyst

Psychedelic stocks are in focus following new legislation from both the Senate and the House that has bipartisan support. The post Dear Psychedelic Stocks Fans, Watch This Key Catalyst appeared first ...

Other symbols: ATAIMNMD
6 months ago - InvestorPlace

COMPASS Pathways appoints Kabir Nath as Chief Executive Officer

Kabir Nath will build upon COMPASS' success and lead the development of novel models of care to accelerate patient access to evidence-based innovation in mental health care

6 months ago - GlobeNewsWire

Wall Street Analysts See a 781% Upside in COMPASS Pathways PLC Sponsored ADR (CMPS): Can the Stock Really Move This High?

The average of price targets set by Wall Street analysts indicates a potential upside of 781.4% in COMPASS Pathways PLC Sponsored ADR (CMPS). While the effectiveness of this highly sought-after metric...

8 months ago - Zacks Investment Research

COMPASS Pathways presents largest ever study of psilocybin therapy, at American Psychiatric Association annual meeting

Positive data from phase IIb study shows potential of COMP360 psilocybin therapy in treatment-resistant depression

8 months ago - GlobeNewsWire